Publication date: Jul 17, 2025
Moderna Receives Full U. S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease. On the CDC’s Child and Adolescent Immunization Schedule by Age, the COVID-19 vaccines are available to the pediatric population under what is called shared clinical decision-making in the guidance. Basically, it’s been reported that the FDA fully approved Moderna as a pediatric COVID 19 vaccine. Moderna submitted their dossier months ago, and the lynchpin of that dossier would be the randomized placebo-controlled trial that they ran in these populations. “Shared clinical decision-making vaccinations are individually based and informed by a decision process between the health care provider and the patient or parent/guardian. Federal Government Changes Course Again on COVID-19 Vaccine Policy. That’s how it first presents. Faust acknowledges there will be a small subset of pediatric patients who will be identified early on, but a large majority will not.
| Concepts | Keywords |
|---|---|
| Fda | Cdc |
| Harvard | Children |
| Influenza | Covid |
| July | Faust |
| Fda | |
| Federal | |
| Guidance | |
| Immunization | |
| July | |
| Moderna | |
| Months | |
| Pediatric | |
| Risk | |
| Vaccine | |
| Years |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | cardiomyopathies |
| drug | DRUGBANK | Coenzyme M |
| pathway | REACTOME | Release |
| disease | MESH | inborn errors of metabolism |
| disease | IDO | process |
| disease | MESH | COVID-19 |
| disease | MESH | Emergency |
| drug | DRUGBANK | Ranitidine |
| disease | MESH | influenza |
| disease | MESH | type 1 diabetes |
| disease | MESH | diabetic ketoacidosis |